Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.78 |
| ▸ | CYSLTR2 | Q9NS75 | 10/20 | 0.78 |
| ▸ | PDE5A | O76074 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11457218 | 0.88 | CYSLTR2 (0.61) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| SCHEMBL11467865 | 0.88 | CYSLTR1 (0.75) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| Fpl-55712 SCHEMBL29766724 | 0.88 | CYSLTR2 (1.00) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| Fpl-55712 SCHEMBL6059336 | 0.88 | CYSLTR2 (1.00) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| Fpl-55712 SCHEMBL1890292 | 0.87 | CYSLTR2 (0.98) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| SCHEMBL11452135 | 0.85 | CYSLTR2 (0.61) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| Fpl-55712 SCHEMBL11532832 | 0.84 | CYSLTR2 (0.89) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| SCHEMBL11467868 | 0.84 | ALDH1A1 (0.55) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| SCHEMBL11452109 | 0.83 | CYSLTR1 (0.59) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 | |
| SCHEMBL10956354 | 0.83 | CYSLTR2 (0.58) | CYSLTR1CYSLTR2PDE5AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | claimed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | claimed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791124-B2 | Use of phosphordiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | UROPEP BIOTECH GBR | 2012-07-05 | — | — | US | disclosed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8106061-B2 | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases | UROPEP BIOTECH GBR (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | disclosed |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | WOLF-GEORG FORSSMANN | 2003-10-23 | — | — | US | disclosed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | disclosed |
| US-20020025969-A1 | Genign prostatic hyperolasia | ERFINDERGEMEINSCHAFT UROPEP GBR (DE) | 2002-02-28 | — | — | US | disclosed |
| WO-1999002161-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | FORSSMANN WOLF GEORG (DE) | 1999-01-21 | — | — | WO | disclosed |
| US-4213903-A | Basic amino acid salts of chromones | FISONS LIMITED (GB) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172365-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | PDE5A, PDE7A, PDE12 | CYSLTR1 1318/4885CYSLTR2 1695/4885PDE5A 1/4885 |
| US-20030199517-A1 | Comprises 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); for treatment of benign prostatic hyperplasia and urination disorders | PDE12, PDE5A, QDPR | CYSLTR1 949/4885CYSLTR2 1016/4885PDE5A 2/4885 |
| US-20020025969-A1 | Genign prostatic hyperolasia | PDE5A, PDE3A, PDE2A | CYSLTR1 1718/4885CYSLTR2 2181/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.